Turkish Study Finds That Colchicine Boosts Kidney Health in COVID-19 Patients

Medical News: The COVID-19 pandemic has impacted not only the respiratory system but also other organs, particularly the kidneys. Acute kidney injury (AKI) is a common complication in COVID-19 patients, leading to serious consequences. Researchers from Sisli Hamidiye Etfal Education and Research Hospital in Istanbul have examined the potential benefits of Colchicine, an anti-inflammatory drug, on kidney health in COVID-19 patients. This Medical News report explores their findings and the implications for treating kidney complications in severe COVID-19 cases.

Turkish Study Finds That Colchicine Boosts Kidney Health in COVID-19 Patients

Understanding Kidney Injury in COVID-19
COVID-19’s progression includes three phases: early infection, a lung-focused pulmonary phase, and finally, a hyperinflammatory phase, often known as a cytokine storm. This last phase can lead to inflammation throughout the body, damaging organs like the kidneys. Acute kidney injury is common, with studies showing that nearly one-third of hospitalized COVID-19 patients develop it. The damage often necessitates intensive care and dialysis, significantly impacting recovery and survival rates.
 
Colchicine as a Treatment Option
Colchicine, known for treating conditions like gout and Familial Mediterranean Fever, has shown potential in managing inflammation. The drug works by blocking tubulin polymerization, which reduces the migration of immune cells that cause inflammation. Its anti-inflammatory and antifibrotic properties suggest it might help reduce the kidney damage often seen in COVID-19 cases. This article delves into the recent study investigating whether Colchicine, when combined with standard COVID-19 care, could benefit kidney health.
 
Study Design and Methodology
The study, conducted in Istanbul from January to June 2021, included 118 hospitalized COVID-19 patients aged between 30 and 60 years. Of these, 50 received Colchicine along with standard care (the Col(+) group), while 68 received only standard COVID-19 care (the Col(-) group). The standard care included antiviral agents, steroids, antithrombotic drugs, and oxygen support as needed.

Researchers tracked various kidney health markers, focusing on serum creatinine (SCr) levels and estimated glomerular filtration rate (eGFR). Both groups underwent routine blood tests to measure inflammation levels, with D-dimer, C-reactive protein (CRP), and lymphocyte counts monitored closely.
 
Results: Improved Kidney Function in the Colchicine Group
The study found notable differences between the Col(+) and Col(-) groups, particularly regarding kidney function and inflammation markers.
 
-Serum Creatinine (SCr) Levels: SCr levels were significantly reduced in the Col(+) group compared to the Col(-) group. Lower SCr levels indicate better kidney function, as they reflect the kidneys’ ability to filter waste from the blood.
 
-Estimated Glomerular Filtration Rate (eGFR): Patients in the Col (+) group showed a more substantial increase in eGFR at discharge, reflecting improved kidney health. Six to twelve months after discharge, the Col(+) group’s eGFR continued to outperform the Col(-) group, highlighting Colchicine’s potential long-term benefits on kidney function.
 
-Inflammatory Markers: D-dimer and CRP levels, which indicate inflammation and blood clot risks, were significantly improved in the Col(+) group compared to the Col(-) group. Patients in the Col(+) group had higher initial CRP levels, but these levels dropped more quickly, suggesting Colchicine’s effectiveness in controlling inflammation.
 
Long-Term Impact of Colchicine on Kidney Health
One of the critical aspects of this study was its long-term follow-up, where researchers examined kidney health six to twelve months post-discharge. The Col(+) group maintained better kidney function, with a more significant number of patients showing eGFR improvements.
 
Furthermore, 11% of patients in the Col(+) group had reduced eGFR at follow-up compared to 24% in the Col(-) group. This data indicates that Colchicine might provide lasting kidney protection for COVID-19 patients who face inflammation-related kidney challenges during infection.
 
Key Study Findings
The study underscores several critical findings regarding Colchicine’s role in supporting kidney health:
-Reduced AKI Occurrence: The Colchicine-treated group experienced lower rates of AKI compared to the control group, suggesting that Colchicine could protect against severe kidney damage in COVID-19 patients.
 
-Enhanced Renal Recovery: Colchicine helped more patients achieve renal recovery faster, with lower rates of diminished kidney function in the long term.
 
-Improved Inflammatory Response: Colchicine’s anti-inflammatory properties helped reduce inflammatory markers more effectively than standard COVID-19 care alone.
 
The Significance of Colchicine in COVID-19 Kidney Treatment
These findings are essential in light of the high AKI rates in COVID-19 patients, particularly among those needing intensive care. AKI is linked to higher mortality rates, and effective treatments are urgently needed. By using Colchicine as an adjunct therapy, healthcare providers may offer better kidney protection to COVID-19 patients, helping them recover kidney function more quickly and reducing the risk of long-term kidney issues.
 
Colchicine’s advantages go beyond its anti-inflammatory properties; it is also widely available, has a well-established safety profile, and is relatively inexpensive. These factors make it an accessible treatment option for hospitals worldwide, particularly in resource-limited settings.
 
Conclusion
This study sheds light on the potential benefits of Colchicine for COVID-19 patients with compromised kidney function. By reducing inflammation and supporting kidney health, Colchicine may help COVID-19 patients avoid severe kidney complications, aiding in both their immediate and long-term recovery. However, additional studies with larger sample sizes and diverse populations are necessary to confirm Colchicine’s benefits in COVID-19 treatment.
 
Overall, these findings suggest that Colchicine, combined with standard care, could become a valuable tool in managing kidney complications in COVID-19 patients. For those struggling with COVID-19-induced inflammation and kidney issues, Colchicine could offer hope for better outcomes.
 
The study findings were published in the peer-reviewed journal: BMC Nephrology.
https://link.springer.com/article/10.1186/s12882-024-03817-2
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/colchicine-reduces-need-for-supplemental-oxygen-and-reduces-risk-of-mortality-in-severe-covid-19-cases
 
https://www.thailandmedical.news/news/university-of-virginia-study-shows-that-colchicine,-a-drug-to-treat-gout-also-helps-improves-survival-rates-of-heart-failure-patients
 
https://www.thailandmedical.news/news/covid-19-drugs-canadian-colcorona-study-shows-that-colchicine-can-reduce-certain-complications-of-covid-19
 
https://www.thailandmedical.news/news/covid-19-drugs-international-study-finds-colchicine-effective-for-non-hospitalized-covid-19-patients
 
https://www.thailandmedical.news/news/breaking-colchicine-an-ancient-pharmaceutical-shows-positive-results-in-early-clinical-trial-to-treat-severe-covid-19-